Experienced in Endometrial Stromal Sarcoma

Benjamin Frey

Erlangen, BY, DE 
Experienced in Endometrial Stromal Sarcoma
Erlangen, BY, DE 
OverviewLocationsClinical Research

Overview

Benjamin Frey practices in Erlangen, Germany. Mr. Frey is rated as an Experienced expert by MediFind in the treatment of Endometrial Stromal Sarcoma. His top areas of expertise are Generalized Pustular Psoriasis (GPP), Head and Neck Squamous Cell Carcinoma (HNSCC), Necrosis, and Pustular Psoriasis.

His clinical research consists of co-authoring 192 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Endometrial Stromal Sarcoma.

Gender
Male

Locations

Erlangen, BY 91054, Germany
Other Locations
Regensburg, BY, Germany
Munich, BY, Germany
Alexander, NW, Germany
Bayern, BY 91054, Germany
Tuebingen, BW 72076, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Analysis of CMV Infections in Patients Suffering From Brain Tumors and Brain Metastases During and After Radio(Chemo)Therapy
Analysis of CMV Infections in Patients Suffering From Brain Tumors and Brain Metastases During and After Radio(Chemo)Therapy
Enrollment Status: Completed
Publish Date: February 16, 2023
Intervention Type: Other
Immunophenotyping From Blood From Patients With Glioblastoma and Anaplastic Astrocytoma Before and During Chemoradiation as Well as During Adjuvant Chemotherapy
Immunophenotyping From Blood From Patients With Glioblastoma and Anaplastic Astrocytoma Before and During Chemoradiation as Well as During Adjuvant Chemotherapy
Enrollment Status: Completed
Publish Date: February 16, 2023
Intervention Type: Other
View 1 Less Clinical Trial

192 Total Publications

Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326.
Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326.
Journal: Cancers
Published: September 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Frey's expertise for a condition
ConditionClose
      View All 32 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile